Comparison of Contrast Agents in Liver MR for the Detection of Hepatic Metastases

• Status: Recruiting
• Trial end date: 2023-12-09
• Target enrollment: 0
• Participant gender: All

Summary

If an abbreviated HBP protocol liver MR with gadobenate dimeglumine is shown clinically comparable to standard of care liver MR with gadoxetate disodium for detecting hepatic metastasis from colorectal cancer, its use will save time, cost, and patients' effort.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Colorado, Denver
• Collaborators: Bracco Diagnostics, Inc; National Cancer Institute (NCI)

Criteria

Inclusion Criteria:

• Colorectal cancer patients

• Age 18-80 years

• No prior treatment including surgery

• Prior imaging with suspected liver metastasis

Exclusion Criteria:

• Age < 18 years or > 80 years

• eGFR < 30 ml/min/1.73 m2

• Previous reaction to gadolinium contrast agents

• History of claustrophobia or movement disorders likely to impact image quality

• Non-MR safe implants or metallic foreign bodies